Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on March 20, 2019. The filing reports a corporate governance event: the expansion of the Board of Directors and the election of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine members.
- New Director Election: Leslie J. Williams was elected as a Class II director, effective March 20, 2019.
- Compensation Grant: Upon election, Ms. Williams received an option to purchase 36,000 shares of common stock at an exercise price of $4.16 per share.
Outlook, Risks, and Contingencies
Management Commentary: The Board acted on the recommendation of the Nominating and Corporate Governance Committee. Ms. Williams brings significant experience as the founder and CEO of ImmusanT, Inc., and former leadership roles at Ventaira Pharmaceuticals, Inc.
Contingencies: The Company entered into a standard Indemnification Agreement with Ms. Williams. Under this agreement, the Company may be required to indemnify her for expenses, including attorneys' fees, judgments, fines, and settlement amounts arising from her service as a director.
Risks: No specific financial or operational risks were disclosed in this filing.
Key Facts for Investor Verification
- Verify the total number of outstanding shares and the dilution impact of the 36,000 new stock options granted to Ms. Williams.
- Confirm the current stock price relative to the $4.16 exercise price of the granted options.
- Review the Company's proxy statement filed on April 23, 2018, for details on the standard compensation structure for non-employee directors.
- Assess the strategic value of Ms. Williams' biotechnology and venture capital background to the Company's pipeline.